OD36 hydrochloride | CAS#1638644-62-8 | RIPK2 inhibitor

MedKoo Cat#: 565615 | Name: OD36 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OD36 is a cell permeable, highly potent, selective, and ATP-competitive inhibitor of receptor-interacting protein 2 (RIPK2, IC₅₀ = 5.3 nM).

Chemical Structure

OD36 HCl

CAS#OD36 HCl

Theoretical Analysis

MedKoo Cat#: 565615

Name: OD36 HCl

CAS#: OD36 HCl

Chemical Formula: C16H16Cl2N4O2

Exact Mass: 366.0650

Molecular Weight: 367.23

Elemental Analysis: C, 52.33; H, 4.39; Cl, 19.31; N, 15.26; O, 8.71

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 610.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1638644-62-8 (free base) OD36 HCl

Synonym

OD36 hydrochloride; OD36 HCl; OD-36; OD 36; RIPK2 inhibitor OD36;

IUPAC/Chemical Name

6-Chloro-10,11,14,17-tetrahydro-13H-1,16-etheno-4,8-metheno-1H-pyrazolo[3,4-g][1,14,4,6]dioxadiazacyclohexadecine hydrochloride

InChi Key

VGOJZWODJXQKMN-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H15ClN4O2.ClH/c17-12-7-11-8-13(9-12)23-6-5-22-4-2-18-15-1-3-21-16(20-15)14(11)10-19-21;/h1,3,7-10H,2,4-6H2,(H,18,20);1H

SMILES Code

ClC1=CC(C2=C3N=C(NCCOCCO4)C=CN3N=C2)=CC4=C1.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM.

In vitro activity:

The most potent compound (OD36) and Gefitinib were profiled against 366 kinases, whereas OD38 was screened against 88 kinases. The kinase profiles, visualized as dendrograms, and the extent of inhibition are graphically represented in Fig. 3A. At 100 nm, both OD36 and OD38 show very good initial specificity, inhibiting few other kinases to the same extent as RIPK2 and showing very high potency with IC50 values in the lower nanomolar range (OD36 having an IC50 of 5.3 nm and OD38 having an IC50 of 14.1 nm, Fig. 3A). Reference: J Biol Chem. 2014 Oct 24;289(43):29651-64. https://pubmed.ncbi.nlm.nih.gov/25213858/

In vivo activity:

As shown in Fig. 5A, both Gefitinib and OD36 inhibited the recruitment of inflammatory cells to the peritoneum, specifically that of neutrophils, and, to a lesser extent, lymphocytes. Statistical analysis of peritoneal lavage cell subsets shows a significant effect of both Gefitinib and OD36 in inhibiting MDP-induced peritonitis (Fig. 5B). Although there was quite some variability between animals, for a number of analytes tested, there was also an observable trend in decrease of secreted chemokines in either the Gefitinib or in the OD36-treated mice (supplemental Fig. S3). These very promising in vivo results for an early-stage RIPK2 inhibitor such as OD36, which also shows potent in vitro activity and good initial selectivity, encourages continued optimization of such RIPK2 inhibitors that will retain potency but in addition display enhanced specificity and an improved half-life in vivo. Reference: J Biol Chem. 2014 Oct 24;289(43):29651-64. https://pubmed.ncbi.nlm.nih.gov/25213858/

	Solvent	mg/mL	mM
Solubility
	Ethanol	1.8	5.01

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 367.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Tigno-Aranjuez JT, Benderitter P, Rombouts F, Deroose F, Bai X, Mattioli B, Cominelli F, Pizarro TT, Hoflack J, Abbott DW. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014 Oct 24;289(43):29651-64. doi: 10.1074/jbc.M114.591388. Epub 2014 Sep 11. PMID: 25213858; PMCID: PMC4207980.

In vitro protocol:

In vivo protocol:

1. Tigno-Aranjuez et al (2014) In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J.Biol.Chem. 289 29651 PMID: 25213858 2. Sánchez-Duffhues et al (2019) Development of macrocycle kinase inhibitors for ALK2 using Fibrodysplasia ossificans progressiva-derived endothelial cells. JBMRPlus 3 e10230 PMID: 31768489